These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15490497)

  • 1. Bevacizumab in colorectal cancer.
    Sharieff W
    N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Boisen MK; Johansen JS; Larsen O; Jensen BV
    Oncology; 2011; 80(1-2):138-9. PubMed ID: 21677460
    [No Abstract]   [Full Text] [Related]  

  • 3. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Kabbinavar F; Kozloff M
    Oncology; 2011; 80(1-2):135-7; author reply 140-1. PubMed ID: 21677459
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    Hurwitz H; Fehrenbacher L; Novotny W; Cartwright T; Hainsworth J; Heim W; Berlin J; Baron A; Griffing S; Holmgren E; Ferrara N; Fyfe G; Rogers B; Ross R; Kabbinavar F
    N Engl J Med; 2004 Jun; 350(23):2335-42. PubMed ID: 15175435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatments for colorectal cancer.
    FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
    [No Abstract]   [Full Text] [Related]  

  • 6. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 7. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
    Kabbinavar FF; Wallace JF; Holmgren E; Yi J; Cella D; Yost KJ; Hurwitz HI
    Oncologist; 2008 Sep; 13(9):1021-9. PubMed ID: 18776057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
    Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
    Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
    [No Abstract]   [Full Text] [Related]  

  • 9. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
    [No Abstract]   [Full Text] [Related]  

  • 10. [Systemic therapy for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Normanno N; Tejpar S; Ciardiello F
    J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improving longevity in advanced intestinal cancer].
    Schmoll HJ
    Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
    [No Abstract]   [Full Text] [Related]  

  • 13. [Progress of chemotherapy in colorectal cancer].
    Komatsu Y
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
    [No Abstract]   [Full Text] [Related]  

  • 14. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 18. Validation of the role of angiogenesis as a chemotherapeutic target.
    Chu E
    Clin Colorectal Cancer; 2003 Aug; 3(2):74-5. PubMed ID: 12952560
    [No Abstract]   [Full Text] [Related]  

  • 19. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
    Pietrantonio F; Garassino MC; Torri V; de Braud F
    Ann Oncol; 2012 Oct; 23(10):2771-2772. PubMed ID: 22875835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.